Familial adenomatous polyposis medical therapy: Difference between revisions
No edit summary |
m (Bot: Removing from Primary care) |
||
| (17 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
The mainstay of treatment for familial adenomatous polyposis is surgery. However, [[non-steroidal anti-inflammatory drug]]s ( | The mainstay of treatment for familial adenomatous polyposis is [[surgery]]. However, [[non-steroidal anti-inflammatory drug]]s ([[NSAID]]s) such as [[sulindac]] and [[celecoxib]] are recommended to decrease the size and number of [[colon polyps]]. | ||
==Medical Therapy== | ==Medical Therapy== | ||
The mainstay of treatment for familial adenomatous polyposis is [[surgery]]. Pharmacologic medical therapies for familial adenomatous polyposis include [[non-steroidal anti-inflammatory drug]]s ([[Non-steroidal anti-inflammatory drug|NSAIDs]]). [[Non-steroidal anti-inflammatory drug]]s ([[Non-steroidal anti-inflammatory drug|NSAIDs]]) decrease the size and number of [[colon polyps]].<ref name="pmid10630758">{{cite journal |vauthors=King JE, Dozois RR, Lindor NM, Ahlquist DA |title=Care of patients and their families with familial adenomatous polyposis |journal=Mayo Clin. Proc. |volume=75 |issue=1 |pages=57–67 |year=2000 |pmid=10630758 |doi=10.4065/75.1.57 |url=}}</ref><ref name="HalfBercovich2009">{{cite journal|last1=Half|first1=Elizabeth|last2=Bercovich|first2=Dani|last3=Rozen|first3=Paul|title=Familial adenomatous polyposis|journal=Orphanet Journal of Rare Diseases|volume=4|issue=1|year=2009|pages=22|issn=1750-1172|doi=10.1186/1750-1172-4-22}}</ref> | |||
* Preferred regimen (1): [[Celecoxib]] 400-600 mg q12h for 6 months<ref name="pmid17360473">{{cite journal |vauthors=Amos-Landgraf JM, Kwong LN, Kendziorski CM, Reichelderfer M, Torrealba J, Weichert J, Haag JD, Chen KS, Waller JL, Gould MN, Dove WF |title=A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=104 |issue=10 |pages=4036–41 |year=2007 |pmid=17360473 |pmc=1805486 |doi=10.1073/pnas.0611690104 |url=}}</ref> | |||
* Preferred regimen (2): [[Sulindac]] 75-150 mg q12h for 4 years | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
| |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Oncology]] | |||
[[Category:Up-To-Date]] | |||
Latest revision as of 21:43, 29 July 2020
|
Familial adenomatous polyposis Microchapters |
|
Differentiating Familial adenomatous polyposis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Familial adenomatous polyposis medical therapy On the Web |
|
American Roentgen Ray Society Images of Familial adenomatous polyposis medical therapy |
|
Directions to Hospitals Treating Familial adenomatous polyposis |
|
Risk calculators and risk factors for Familial adenomatous polyposis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2], Mohamad Alkateb, MBBCh [3]
Overview
The mainstay of treatment for familial adenomatous polyposis is surgery. However, non-steroidal anti-inflammatory drugs (NSAIDs) such as sulindac and celecoxib are recommended to decrease the size and number of colon polyps.
Medical Therapy
The mainstay of treatment for familial adenomatous polyposis is surgery. Pharmacologic medical therapies for familial adenomatous polyposis include non-steroidal anti-inflammatory drugs (NSAIDs). Non-steroidal anti-inflammatory drugs (NSAIDs) decrease the size and number of colon polyps.[1][2]
- Preferred regimen (1): Celecoxib 400-600 mg q12h for 6 months[3]
- Preferred regimen (2): Sulindac 75-150 mg q12h for 4 years
References
- ↑ King JE, Dozois RR, Lindor NM, Ahlquist DA (2000). "Care of patients and their families with familial adenomatous polyposis". Mayo Clin. Proc. 75 (1): 57–67. doi:10.4065/75.1.57. PMID 10630758.
- ↑ Half, Elizabeth; Bercovich, Dani; Rozen, Paul (2009). "Familial adenomatous polyposis". Orphanet Journal of Rare Diseases. 4 (1): 22. doi:10.1186/1750-1172-4-22. ISSN 1750-1172.
- ↑ Amos-Landgraf JM, Kwong LN, Kendziorski CM, Reichelderfer M, Torrealba J, Weichert J, Haag JD, Chen KS, Waller JL, Gould MN, Dove WF (2007). "A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer". Proc. Natl. Acad. Sci. U.S.A. 104 (10): 4036–41. doi:10.1073/pnas.0611690104. PMC 1805486. PMID 17360473.